Aug 7 (Reuters) - Medical device maker Solventum ( SOLV )

raised full-year adjusted profit forecast on Thursday,

driven by strong sales of its wound care and surgical

sterilization products alongside lower expenses.

Medical device makers have benefited from a surge in demand

as more people, particularly older Americans, seek health care

services and surgical procedures.

Minnesota-based Solventum ( SOLV ) is one of the largest providers of

sterilization devices, wound dressings, medical tape and other

hospital consumables used by healthcare facilities.

More than half of its revenue comes from its MedSurg

business, which provides wound dressings and surgical equipment.

Sales in the segment rose 4.8% to $1.22 billion during the

quarter.

Earlier in the day, Solventum's ( SOLV ) peer Zimmer Biomet Holdings ( ZBH )

also raised its annual profit forecast as it anticipates

lower-than-expected tariff impact.

Last quarter, Solventum ( SOLV ) estimated tariff headwinds of $80

million to $100 million for 2025, translating to an earnings per

share impact of 35 cents to 45 cents.

However, analysts now note that Solventum's ( SOLV ) tariff risk has

eased following the recent de-escalation of U.S.-China trade

tensions.

The company now expects its 2025 adjusted profit per share

to be in the range of $5.80 to $5.95, compared with previously

projected adjusted profit of $5.45 to $5.65.

On an adjusted basis, the company earned second-quarter

profit per share of $1.69, compared with analysts' average

estimates of $1.44, according to data compiled by LSEG.